eoadjuvant S-1 therapy for resectable pancreatic cancer patients; A phase2 study

Phase 2

• Conditions: pancreatic cancer

• Registration Number: JPRN-UMIN000013031
• Lead Sponsor: Hokkaido Pancreatic Cancer Study Group (HOPS)

Brief Summary

2year disease free survival ITT(N=49):40.8% 2year disease free survival Resection(N=43):46.5% 2year overall survival ITT(N=49):73.2% 2year overall survival Resection(N=43):76.7%

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2014-01-31
• Study Completion: 2018-02-28
• Last Update Posted: 20 November 2023

Recruitment & Eligibility

• Status: Complete: follow-up complete
• Sex: All
• Target Recruitment: 51

Inclusion Criteria

Not provided

Exclusion Criteria

1) Treatment history of S-1 2) Treatment history of a pancreatic cancer 3) Regular use of frucitocin, fenitoin or warfarin 4) Patients who can' t receive neither iodic drug because of drug allergy 5) Lung fibrosis or intestinal pneumonia, and anamnesis or imaging findings 6) Massive pleural or abdominal effusion 7) Severe infection 8) Watery diarrhea 9) Uncontrolled diabetes 10) Simultaneous or metachronous (within 3 years) double cancers 11) Hemorrhagic peptic ulcer 12) Patients with severe disease 13) Patients requiring systemic steroids medication 14) Severe mental illness 15) Severe drug hypersensitivity 16)Pregnant females, possibly pregnant females, females wishing to become pregnant or Males that are currently attempting to produce a pregnancy 17)Patients seems inadequate for this study by investigators

Study & Design

• Study Type: Interventional
• Study Design: Not specified